公司資料
Aptevo Therapeutics 股價、新聞與催化劑
- 股票代碼:
- APVO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.81 USD (-4.42%)
收盤價
最後更新: 2026年8月17日
6.28M USD
市值
股價為何變動
Following the latest company update, “Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results”, APVO closed down 13.5% at $2.94 on Aug 14, 2026. The move occurred in the trading session associated with this earnings update.
公司概覽
Multispecific Immunotherapy Platforms
Aptevo Therapeutics is a clinical-stage biotechnology company developing multispecific immunotherapies for cancer. Its ADAPTIR and ADAPTIR-FLEX platforms are designed to create molecules that engage multiple immune and tumor targets within a single therapeutic construct.
Mipletamig
Mipletamig is a bispecific antibody candidate designed to redirect T cells toward CD123-expressing leukemia cells. Aptevo is developing the program in frontline acute myeloid leukemia in combination with venetoclax and azacitidine.
RAINIER Frontline AML Study
RAINIER is a Phase 1b/2 study evaluating mipletamig with venetoclax and azacitidine in newly diagnosed AML. The Phase 1b portion is focused on dose optimization and selection of a recommended Phase 2 dose before the program advances into a larger expansion stage.
APVO451
APVO451 is a trispecific solid-tumor candidate directed at nectin-4 and designed to engage immune effector mechanisms. The program is in candidate-selection work ahead of IND-enabling development.
Radiopharmaceutical Collaboration
Aptevo is also working with Niowave under a 50-50 collaboration to develop radiopharmaceutical oncology programs. The partnership combines Aptevo's multispecific binding constructs with Niowave's radioisotope capabilities and may encompass as many as three programs.
未來催化劑
- Completion of RAINIER Phase 1b and selection of the recommended Phase 2 dose for mipletamig by year-end 2026.
- Selection of the APVO451 development candidate by year-end 2026.
- Regulatory interaction regarding the mipletamig Phase 2 program in Q1 2027.
- Initiation of IND-enabling studies for APVO451 in Q1 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。